# Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder

> **NCT03386851** · — · COMPLETED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 1030 (actual)

## Conditions studied

- Schizophrenia
- Bipolar 1 Disorder

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03386851
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-13
- **Primary completion:** 2021-05-25
- **Final completion:** 2021-05-25
- **Target enrollment:** 1030 (ACTUAL)
- **Last updated:** 2022-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386851, "Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03386851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*